Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

E Gerdts; G de Simone; Birthe Lund; P M Okin; K Wachtell; K Boman; M S Nieminen; B Dahlöf; R B Devereux

doi:10.1016/j.numecd.2011.03.008

Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

E Gerdts, G de Simone, Birthe Lund, P M Okin, K Wachtell, K Boman, M S Nieminen, B Dahlöf, R B Devereux

26 Citations (Scopus)

Abstract

BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p

Original language	English
Journal	Nutrition, Metabolism & Cardiovascular Diseases
Volume	23
Issue number	2
Pages (from-to)	122-129
ISSN	0939-4753
DOIs	https://doi.org/10.1016/j.numecd.2011.03.008
Publication status	Published - 2013

Access to Document

10.1016/j.numecd.2011.03.008

Cite this

@article{4e770e5d6c69419c8b208e3113bd2dfd,

title = "Impact of overweight and obesity on cardiac benefit of antihypertensive treatment",

abstract = "BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p ",

author = "E Gerdts and {de Simone}, G and Birthe Lund and Okin, {P M} and K Wachtell and K Boman and Nieminen, {M S} and B Dahl{\"o}f and Devereux, {R B}",

year = "2013",

doi = "10.1016/j.numecd.2011.03.008",

language = "English",

volume = "23",

pages = "122--129",

journal = "Nutrition, Metabolism & Cardiovascular Diseases",

issn = "0939-4753",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

AU - Gerdts, E

AU - de Simone, G

AU - Lund, Birthe

AU - Okin, P M

AU - Wachtell, K

AU - Boman, K

AU - Nieminen, M S

AU - Dahlöf, B

AU - Devereux, R B

PY - 2013

Y1 - 2013

N2 - BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p

AB - BACKGROUND AND AIMS: Increased body mass index (BMI) has been associated with increased cardiovascular morbidity and mortality in hypertension. Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment. METHODS AND RESULTS: Annual BMI, echocardiograms and cardiovascular events were recorded in 875 hypertensive patients with LV hypertrophy during 4.8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy. Patients were grouped by baseline BMI into normal (n = 282), overweight (n = 405), obese (n = 150) and severely obese groups (n = 38) (BMI ≤24.9, 25.0-29.9, 30.0-34.9, and ≥35.0 kg/m(2), respectively). At study end, residual LV hypertrophy was present in 54% of obese and 79% of severely obese patients compared to 31% of normal weight patients (both p

U2 - 10.1016/j.numecd.2011.03.008

DO - 10.1016/j.numecd.2011.03.008

M3 - Journal article

C2 - 21775111

SN - 0939-4753

VL - 23

SP - 122

EP - 129

JO - Nutrition, Metabolism & Cardiovascular Diseases

JF - Nutrition, Metabolism & Cardiovascular Diseases

IS - 2

ER -

Impact of overweight and obesity on cardiac benefit of antihypertensive treatment

Abstract

Access to Document

Fingerprint

Cite this